They warn AstraZeneca may have included “outdated” data in US vaccine trials.

AstraZeneca may have included “outdated” data in its US clinical trials on the covid-19 vaccinethe US drug regulator said, citing a group of independent experts.

The group expressed “concern that AstraZeneca has included outdated information in this trial, which could have resulted in an incomplete estimate of the effectiveness” of the vaccine, noted the National Institute of Allergies and Infectious Diseases (NIAID), in a statement released Monday evening.

“We urge the laboratory to work with the DSMB (Data and Safety Monitoring Board, a group of independent experts responsible for overseeing clinical trials) to examine the efficacy and ensure that the most precise, specific and day are published as soon as possible»Addition of text.

The statement comes after AstraZeneca said on Monday that trials in more than 32,000 people in the United States showed the vaccine to be 79% effective in preventing symptomatic COVID-19 in the population and 100% in preventing severe forms of COVID-19. Illness and hospitalization, and further ensuring that the risk of blood clots does not increase.

The AstraZeneca coronavirus vaccine is cheaper and easier to store than others, but several countries temporarily suspended vaccination with the drug last week due to isolated cases of blood clots in some people who had received it.

The The European Medicines Agency (EMA) deemed it “safe and effective” and the drug was again administered in several countries.

However, mistrust is still present and a YouGov survey, carried out between March 12 and 18, showed that a majority of respondents in major European countries – including Germany, France, Spain and the ‘Italy – wary of safety of AstraZeneca vaccine.

Prior to the publication of this report, Anthony Fauci, the leading infectious disease expert for the United States government, on Monday celebrated the results of the new study in the country of the COVID-19 vaccine developed by Oxford / AstraZeneca, which showed an assumed efficacy of 79 percent in symptomatic cases of the disease and 100 percent protection against severe cases.

“The good news is that there was comparable efficacy for all ethnicities and ages, i.e. very good efficacy, 79.9 percent, among participants aged 65 or older.“, Fauci said during the White House COVID-19 response team briefing.

KEEP READING: